|
| BMS-955176(TFA) Basic information |
| BMS-955176(TFA) Chemical Properties |
| BMS-955176(TFA) Usage And Synthesis |
Description | GSK3532795, also known as BMS-955176, is a potent, orally active, second-generation HIV-1 maturation inhibitor (MI) that advanced through phase IIb clinical trials. GSK3532795 combines broad coverage of polymorphic viruses (EC50 <15 nM toward a panel of common polymorphisms representative of 96.5% HIV-1 subtype B virus) with a favorable pharmacokinetic profile in preclinical species. |
| BMS-955176(TFA) Preparation Products And Raw materials |
|